Favorable-Risk mRCC: Combination Regimens Vs Single-Agent Therapy
April 7th 2021Factors that oncologists need to consider when deciding whether to initiate single-agent therapy or a novel combination regimen as frontline treatment for patients with favorable-risk metastatic renal cell carcinoma.
Read More
Current RCC Treatment Limitations
January 29th 2021Health care experts remark on current unmet needs associated with the use of novel therapies, such as immunotherapies, and targeted treatments for metastatic renal cell carcinoma and share advice on best practices when managing patients in the community.
Read More
Lenvatinib Combination Data in mRCC
January 29th 2021Robert Alter, MD, highlights various trial data on the management of advanced renal cell carcinoma with the combination of lenvatinib and everolimus, also commenting on the potential outcomes associated with the use of lenvatinib with pembrolizumab.
Read More
Risk Stratification in Renal Cell Carcinoma
December 23rd 2020A historical overview regarding the development of parameters used to help stratify risk in patients with renal cell carcinoma and the relevance of current models in the context of selecting systemic therapy to treat appropriate patients.
Read More